Back to today’s briefing

Story perspectives

AstraZeneca Invests $15 Billion in China's Drug Manufacturing Expansion

3/21/2026

50 7

Summary

Story summary

AstraZeneca plans drug manufacturing facilities in Guangzhou and Shanghai.
The company will also establish a cell-therapy production base in Shanghai's Lingang Special Area.
The Guangzhou facility will produce actinium-225-based treatments for prostate cancer.
The move is part of a US$15 billion commitment to the Chinese market by 2030 announced during UK Prime Minister Keir Starmer's January visit to Beijing.

1 of 1

Story summary

AstraZeneca plans drug manufacturing facilities in Guangzhou and Shanghai.
The company will also establish a cell-therapy production base in Shanghai's Lingang Special Area.
The Guangzhou facility will produce actinium-225-based treatments for prostate cancer.
The move is part of a US$15 billion commitment to the Chinese market by 2030 announced during UK Prime Minister Keir Starmer's January visit to Beijing.